Catalyst
Key milestones include interim results and final outcomes at the 48-week mark, as well as any safety concerns raised during the trial.
Date
June 10, 2026
Phase
N/A
Status
watch
Signal score
8.0
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.